BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 32977006)

  • 1. Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation.
    Pirisinu M; Pham TC; Zhang DX; Hong TN; Nguyen LT; Le MT
    Semin Cancer Biol; 2022 May; 80():340-355. PubMed ID: 32977006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New approaches in extracellular vesicle engineering for improving the efficacy of anti-cancer therapies.
    Jayasinghe MK; Tan M; Peng B; Yang Y; Sethi G; Pirisinu M; Le MTN
    Semin Cancer Biol; 2021 Sep; 74():62-78. PubMed ID: 33609665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular Vesicle (EV) biohybrid systems for cancer therapy: Recent advances and future perspectives.
    Ou YH; Liang J; Czarny B; Wacker MG; Yu V; Wang JW; Pastorin G
    Semin Cancer Biol; 2021 Sep; 74():45-61. PubMed ID: 33609664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular vesicles for drug delivery.
    Vader P; Mol EA; Pasterkamp G; Schiffelers RM
    Adv Drug Deliv Rev; 2016 Nov; 106(Pt A):148-156. PubMed ID: 26928656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular Vesicles as an Efficient and Versatile System for Drug Delivery.
    Dang XTT; Kavishka JM; Zhang DX; Pirisinu M; Le MTN
    Cells; 2020 Sep; 9(10):. PubMed ID: 33003285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane Derived Vesicles as Biomimetic Carriers for Targeted Drug Delivery System.
    Zhang LY; Yang X; Wang SB; Chen H; Pan HY; Hu ZM
    Curr Top Med Chem; 2020; 20(27):2472-2492. PubMed ID: 32962615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular Vesicles - Advanced Nanocarriers in Cancer Therapy: Progress and Achievements.
    Huyan T; Li H; Peng H; Chen J; Yang R; Zhang W; Li Q
    Int J Nanomedicine; 2020; 15():6485-6502. PubMed ID: 32922012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
    Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
    J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer Therapy Targeting Cancer-Derived Extracellular Vesicles.
    Cheng X; Henick BS; Cheng K
    ACS Nano; 2024 Mar; 18(9):6748-6765. PubMed ID: 38393984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular vesicles in cancer nanomedicine.
    Tarasov VV; Svistunov AA; Chubarev VN; Dostdar SA; Sokolov AV; Brzecka A; Sukocheva O; Neganova ME; Klochkov SG; Somasundaram SG; Kirkland CE; Aliev G
    Semin Cancer Biol; 2021 Feb; 69():212-225. PubMed ID: 31421263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular Vesicles as Drug Delivery Vehicles to the Central Nervous System.
    Shahjin F; Chand S; Yelamanchili SV
    J Neuroimmune Pharmacol; 2020 Sep; 15(3):443-458. PubMed ID: 31485884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering Extracellular Vesicles as Delivery Systems in Therapeutic Applications.
    Wang L; Wang D; Ye Z; Xu J
    Adv Sci (Weinh); 2023 Jun; 10(17):e2300552. PubMed ID: 37080941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for the use of Extracellular Vesicles for the Delivery of Therapeutics.
    Sil S; Dagur RS; Liao K; Peeples ES; Hu G; Periyasamy P; Buch S
    J Neuroimmune Pharmacol; 2020 Sep; 15(3):422-442. PubMed ID: 31456107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances on extracellular vesicles in therapeutic delivery: Challenges, solutions, and opportunities.
    Lu M; Xing H; Yang Z; Sun Y; Yang T; Zhao X; Cai C; Wang D; Ding P
    Eur J Pharm Biopharm; 2017 Oct; 119():381-395. PubMed ID: 28739288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous cancer cell-derived extracellular vesicles as drug-delivery systems: a systematic review of preclinical and clinical findings and translational implications.
    Li YJ; Wu JY; Hu XB; Wang JM; Xiang DX
    Nanomedicine (Lond); 2019 Feb; 14(4):493-509. PubMed ID: 30694095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organically derived exosomes as carriers of anticancer drugs and imaging agents for cancer treatment.
    Srivastava A; Rathore S; Munshi A; Ramesh R
    Semin Cancer Biol; 2022 Nov; 86(Pt 1):80-100. PubMed ID: 35192929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and characterization of extracellular vesicles and future directions in diagnosis and therapy.
    De Sousa KP; Rossi I; Abdullahi M; Ramirez MI; Stratton D; Inal JM
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023 Jan; 15(1):e1835. PubMed ID: 35898167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source.
    Meng W; He C; Hao Y; Wang L; Li L; Zhu G
    Drug Deliv; 2020 Dec; 27(1):585-598. PubMed ID: 32264719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular Vesicles in the Development of Cancer Therapeutics.
    Sun H; Burrola S; Wu J; Ding WQ
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32847103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular vesicle-based therapeutics: Extracellular vesicles as therapeutic targets and agents.
    Takahashi Y; Takakura Y
    Pharmacol Ther; 2023 Feb; 242():108352. PubMed ID: 36702209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.